A. Calles Blanco - Medical Oncology Department, Hospital General Universitario Gregorio Marañon

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy

N. Peled, J. Mazieres, D.M. Kowalski,W-S. Lam, M.J. Hochmair, M. Majem,S.H. Kim,A. Calles Blanco, K. Cuppens, I.A. Casarini, O. Bylicki, B. Shim,

Immuno-Oncology and Technology (2023): 100593

引用0浏览0引用

1476P Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study

A. Piedra,S. Martinez Recio, A. Hernandez Gonzalez, M.T. Moran Bueno,E. Arriola, J. Recuero-Borau,M. Cobo Dols, P. Cordeiro González,J. Mosquera Martinez,M.R. García-Campelo,A. Calles Blanco,R.M. Alvarez,

Annals of Oncology (2023): S835-S836

引用0浏览0引用

1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor

L. Mezquita, E. Xenophontos, Y. Pretzenbaher, C. Sureda, E. Nadal, K. Al-Rabi, G. Rousseau Bussac, S. Ponce Aix, I.G. Sullivan,A. Calles Blanco, N. Cloarec,J. De Langen,

Annals of Oncology (2023): S849-S850

引用0浏览0引用

1989MO Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study

A. Calles Blanco,A.F. Navarro Mendivil,B. Doger de Spéville, E. Álvarez Colomé,M.J. De Miguel Luken,R.M. Alvarez,V. Moreno Garcia,J. ramon,M. Arregui Valles,E. Corral de la Fuente, D. Alcalá, M. Fernández,

Annals of Oncology (2023): S1060-S1061

引用0浏览0引用

Predictive Model For Survival In Advanced Non-Small Cell Lung Cancer (Nsclc) Treated With Frontline Pembrolizumab

X. Mielgo Rubio,M. E. Olmedo Garcia,M. Sereno Moyano, C. Aguado,J. A. Nunez,M. Domine Gomez,A. M. Sanchez Pena, I. Nalda Ariza,S. Cerezo Gonzalez,R. Alvarez Cabellos, L. Cabezon Gutierrez, C. Pangua Mendez,

ANNALS OF ONCOLOGY（2019）

引用4浏览0引用

P2.14-29 Clinical Impact of Next-Generation Sequencing (NGS) in Blood Liquid Biopsies for Treatment Decisions in Advanced NSCLC

M. Garcia Pardo,I. Martinez Delfrade,I. Aparicio Salcedo,M. Arregui Valles,M. Alva Bianchi,V. Tirado Anula,R. Alvarez,A. Calles Blanco

JOURNAL OF THORACIC ONCOLOGY（2019）

引用0浏览0引用

P1.16-09 Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort

G. Metro,D. Signorelli,J. Rey-Cobo, M. Banini,P. Economopoulou,G. Lo Russo,P. Baxevanos, F. Roila,A. De Toma,G. Banna,A. Christopoulou,B. Jimenez,

JOURNAL OF THORACIC ONCOLOGY（2019）

引用0浏览0引用

100P Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer

I Marquez-Rodas, F Longo,S Ponce Aix, M Jove, B Rubio,A Calles Blanco,M E Rodriguez-Ruiz,M Ponz-Sarvise,E Castañon, P Gajate, C Sempere-Ortega, E Jimenez-Aguilar,

Annals of Oncology（2019）

引用3浏览0引用

Applicability Of Lung Immune Prognostic Index (Lipi) To Predict Efficacy Of First-Line Pembrolizumab In Advanced Non-Small Cell Lung Cancer (Nsclc)

X. Mielgo Rubio,A. Gomez Rueda, M. Antonanzas, S. Falagan,J. A. Nunez,A. M. Sanchez Pena, I. Gomez-Barreda,E. Martinez Moreno,S. Cerezo Gonzalez, L. Cabezon Gutierrez,J. M. Sanchez Torres,B. E. Jimenez Munarriz,

ANNALS OF ONCOLOGY（2019）

引用9浏览0引用

EP1.01-92 Effectiveness of Second-Line Treatment with Nintedanib + Docetaxel (ND) in Patients with Metastatic Lung Adenocarcinoma

J.F. Cordoba Ortega, C. Adaniel,S. Morales, A. Gasol, J. Veas,A. Rodriguez,A. Calles Blanco, A. Salud

JOURNAL OF THORACIC ONCOLOGY（2019）

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn